Less than a week after Eisai and Biogen won accelerated approval from the FDA for their Alzheimer’s drug lecanemab, Executive Editor Drew Armstrong spoke one-on-one with Eisai’s US CEO Ivan Cheung, who also leads the company’s Alzheimer’s efforts. This transcript has been edited for brevity and clarity.
Welcome everyone. I’m Drew Armstrong, the executive editor over at Endpoints News, and I’m exceptionally pleased to be joined by Ivan Cheung from Eisai. He runs the US business and oversees the Alzheimer’s program there. Obviously, you all have had some enormous news in the last week with the accelerated approval of Lecanemab, and congratulations on that. It’s obviously a huge moment for the field, a huge moment for your company. I want to jump right in because we have 30 minutes and so much to cover. I’m incredibly excited to get this chance to talk to you. Now, that I’m in San Francisco, you’re in New Jersey. I’m sorry we aren’t able to be together in person, but tons of news from you all. You’ve gotten this accelerated approval.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.